• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双重 HDAC 和 PI3K 抑制消除 NFκB 和 FOXM1 介导的 DNA 损伤反应,增强儿童高级别脑胶质瘤的放射敏感性。

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

机构信息

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Department of Neurology, University of California, San Francisco, San Francisco, California.

出版信息

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

DOI:10.1158/0008-5472.CAN-17-3691
PMID:29760046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6294442/
Abstract

Aberrant chromatin remodeling and activation of the PI3K pathway have been identified as important mediators of pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) pathogenesis. As inhibition of these pathways are promising therapeutic avenues and radiation is the only modality to prolong survival of patients with DIPG, we sought to explore radiosensitizing functions of such inhibition and to explore mechanisms of action of such agents. Here, we demonstrate that combined treatment with radiotherapy and CUDC-907, a novel first-in-class dual inhibitor of histone deacetylases (HDAC) and PI3K, evokes a potent cytotoxic response in pHGG and DIPG models. CUDC-907 modulated DNA damage response by inhibiting radiation-induced DNA repair pathways including homologous recombination and nonhomologous end joining. The radiosensitizing effects of CUDC-907 were mediated by decreased NFκB/Forkhead box M1 (FOXM1) recruitment to promoters of genes involved in the DNA damage response; exogenous expression of NFκB/FOXM1 protected from CUDC-907-induced cytotoxicity. Together, these findings reveal CUDC-907 as a novel radiosensitizer with potent antitumor activity in pHGG and DIPG and provide a preclinical rationale for the combination of CUDC-907 with radiotherapy as a novel therapeutic strategy against pHGG and DIPG. More globally, we have identified NFκB and FOXM1 and their downstream transcriptional elements as critical targets for new treatments for pHGG and DIPG. These findings describe the radiosensitizing effect of a novel agent in pediatric high-grade gliomas, addressing a critical unmet need of increasing the radiation sensitivity of these highly aggressive tumors. .

摘要

染色质重塑和 PI3K 通路的激活已被确定为小儿高级别神经胶质瘤 (pHGG) 和弥漫性内在脑桥神经胶质瘤 (DIPG) 发病机制的重要介质。由于抑制这些通路是很有前途的治疗途径,而放疗是唯一能延长 DIPG 患者生存时间的方法,因此我们试图探索这种抑制的放射增敏作用,并探索这些药物的作用机制。在这里,我们证明了与放疗联合使用 CUDC-907(一种新型的组蛋白去乙酰化酶 (HDAC) 和 PI3K 的双重抑制剂),可在 pHGG 和 DIPG 模型中引发强烈的细胞毒性反应。CUDC-907 通过抑制辐射诱导的 DNA 修复途径,包括同源重组和非同源末端连接,来调节 DNA 损伤反应。CUDC-907 的放射增敏作用是通过减少 NFκB/叉头框 M1 (FOXM1) 募集到参与 DNA 损伤反应的基因启动子上来介导的;NFκB/FOXM1 的外源性表达可防止 CUDC-907 诱导的细胞毒性。总之,这些发现揭示了 CUDC-907 作为一种新型的放射增敏剂,在 pHGG 和 DIPG 中具有很强的抗肿瘤活性,并为 CUDC-907 与放疗联合作为 pHGG 和 DIPG 的新型治疗策略提供了临床前依据。更广泛地说,我们已经确定了 NFκB 和 FOXM1 及其下游转录因子是 pHGG 和 DIPG 新治疗方法的关键靶点。这些发现描述了一种新型药物在小儿高级别神经胶质瘤中的放射增敏作用,解决了增加这些高度侵袭性肿瘤的放射敏感性的关键未满足需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/20c285da0b59/nihms-994560-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/a009ffa11c8f/nihms-994560-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/5d4fba475c91/nihms-994560-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/a6c869ea6009/nihms-994560-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/1746e1646414/nihms-994560-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/5a2eb43b1dcc/nihms-994560-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/0d8073a4b543/nihms-994560-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/20c285da0b59/nihms-994560-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/a009ffa11c8f/nihms-994560-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/5d4fba475c91/nihms-994560-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/a6c869ea6009/nihms-994560-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/1746e1646414/nihms-994560-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/5a2eb43b1dcc/nihms-994560-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/0d8073a4b543/nihms-994560-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5db3/6294442/20c285da0b59/nihms-994560-f0007.jpg

相似文献

1
Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.双重 HDAC 和 PI3K 抑制消除 NFκB 和 FOXM1 介导的 DNA 损伤反应,增强儿童高级别脑胶质瘤的放射敏感性。
Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.
2
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.双重 HDAC-PI3K 抑制剂 CUDC-907 在小细胞肺癌中表现出单药活性,并与 PARP 抑制剂奥拉帕利协同作用。
J Exp Clin Cancer Res. 2020 Oct 17;39(1):219. doi: 10.1186/s13046-020-01728-2.
3
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.新型 HDAC 和 PI3K 双重抑制剂 CUDC-907 在胰腺癌中的抗肿瘤活性及耐药机制。
Cancer Chemother Pharmacol. 2021 Mar;87(3):415-423. doi: 10.1007/s00280-020-04210-0. Epub 2021 Jan 3.
4
CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.CUDC-907,一种新型的双重 PI3K 和组蛋白去乙酰化酶抑制剂,在前列腺癌中的应用:抗肿瘤活性和作用机制的分子研究。
J Cell Mol Med. 2020 Jul;24(13):7239-7253. doi: 10.1111/jcmm.15281. Epub 2020 May 27.
5
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.新型 PI3K 和组蛋白去乙酰化酶双重抑制剂 CUDC-907 在急性髓系白血病中的抗白血病活性及作用机制。
Haematologica. 2019 Nov;104(11):2225-2240. doi: 10.3324/haematol.2018.201343. Epub 2019 Feb 28.
6
Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.脂质体阿霉素对流增强递送治疗小儿弥漫性脑桥内在型胶质瘤和丘脑高级别胶质瘤的临床前评估
J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.
7
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.组蛋白 H3 去甲基化酶抑制在弥漫性内在脑桥胶质瘤中的放射增敏作用。
Clin Cancer Res. 2019 Sep 15;25(18):5572-5583. doi: 10.1158/1078-0432.CCR-18-3890. Epub 2019 Jun 21.
8
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.组蛋白去乙酰化酶和磷酸肌醇3激酶的双重抑制增强了对B细胞淋巴瘤的治疗活性。
Oncotarget. 2017 Feb 21;8(8):14017-14028. doi: 10.18632/oncotarget.14876.
9
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.AXL 和组蛋白去乙酰化酶抑制联合治疗逆转弥漫性内在脑桥胶质瘤中的间质转化。
Clin Cancer Res. 2020 Jul 1;26(13):3319-3332. doi: 10.1158/1078-0432.CCR-19-3538. Epub 2020 Mar 12.
10
Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.Delta-24-RGD 与放射疗法联合应用于弥漫性内在脑桥胶质瘤和小儿高级别脑胶质瘤模型中具有强大的抗肿瘤作用。
Acta Neuropathol Commun. 2019 Apr 29;7(1):64. doi: 10.1186/s40478-019-0714-6.

引用本文的文献

1
Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models.共济失调毛细血管扩张症突变激酶的破坏增强了空间定向弥漫性中线胶质瘤模型中的放射治疗效果。
J Clin Invest. 2025 Apr 17;135(12). doi: 10.1172/JCI179395. eCollection 2025 Jun 16.
2
The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma.双HDAC/PI3K抑制剂CUDC-907可抑制MYC驱动的3型髓母细胞瘤的生长和增殖。
Cell Death Discov. 2025 Apr 14;11(1):172. doi: 10.1038/s41420-025-02470-4.
3
Key genes altered in glioblastoma based on bioinformatics (Review).

本文引用的文献

1
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.弥漫性脑桥内在型胶质瘤中的转录依赖性
Cancer Cell. 2017 May 8;31(5):635-652.e6. doi: 10.1016/j.ccell.2017.03.011. Epub 2017 Apr 20.
2
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.组蛋白去乙酰化酶和磷酸肌醇3激酶的双重抑制增强了对B细胞淋巴瘤的治疗活性。
Oncotarget. 2017 Feb 21;8(8):14017-14028. doi: 10.18632/oncotarget.14876.
3
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
基于生物信息学的胶质母细胞瘤中改变的关键基因(综述)
Oncol Lett. 2025 Mar 24;29(5):243. doi: 10.3892/ol.2025.14989. eCollection 2025 May.
4
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer.MK-1775与CUDC-907联合对前列腺癌的协同抗肿瘤作用
Invest New Drugs. 2025 Feb;43(1):157-166. doi: 10.1007/s10637-024-01490-8. Epub 2025 Jan 27.
5
Progress Toward Epigenetic Targeted Therapies for Childhood Cancer.儿童癌症表观遗传靶向治疗的进展
Cancers (Basel). 2024 Dec 12;16(24):4149. doi: 10.3390/cancers16244149.
6
Exploring glioma heterogeneity through omics networks: from gene network discovery to causal insights and patient stratification.通过组学网络探索胶质瘤异质性:从基因网络发现到因果洞察和患者分层。
BioData Min. 2024 Dec 18;17(1):56. doi: 10.1186/s13040-024-00411-y.
7
SOX10 mediates glioblastoma cell-state plasticity.SOX10 介导胶质母细胞瘤细胞状态可塑性。
EMBO Rep. 2024 Nov;25(11):5113-5140. doi: 10.1038/s44319-024-00258-8. Epub 2024 Sep 16.
8
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.组蛋白去乙酰化酶和多聚(ADP-核糖)聚合酶抑制剂与地西他滨在乳腺癌和卵巢癌细胞中的协同细胞毒性:对新型治疗联合的启示。
Int J Mol Sci. 2024 Aug 26;25(17):9241. doi: 10.3390/ijms25179241.
9
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells.缺氧诱导因子1(HIF1)、原癌基因c-Myc和抑癌基因p53在胶质瘤细胞中的代谢作用
Metabolites. 2024 Apr 25;14(5):249. doi: 10.3390/metabo14050249.
10
NCAPH serves as a prognostic factor and promotes the tumor progression in glioma through PI3K/AKT signaling pathway.NCAPH作为一种预后因素,通过PI3K/AKT信号通路促进胶质瘤的肿瘤进展。
Mol Cell Biochem. 2025 Jan;480(1):589-605. doi: 10.1007/s11010-024-04976-4. Epub 2024 Apr 8.
一种用于小儿低级别星形细胞瘤非经典BRAF癌蛋白的可穿透血脑屏障的RAF二聚体拮抗剂。
Neuro Oncol. 2017 Jun 1;19(6):774-785. doi: 10.1093/neuonc/now261.
4
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.双组蛋白去乙酰化酶和磷脂酰肌醇-3-激酶抑制剂CUDC-907下调MYC并抑制MYC依赖性癌症的生长。
Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.
5
The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair.组蛋白去乙酰化酶对DNA损伤信号传导和DNA修复的多方面影响。
Nucleic Acids Res. 2016 Dec 1;44(21):10017-10030. doi: 10.1093/nar/gkw922. Epub 2016 Oct 13.
6
c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.c-Myc 调节和乙酰化是癌症中关键的 HDAC 抑制剂靶标。
Clin Cancer Res. 2017 May 15;23(10):2542-2555. doi: 10.1158/1078-0432.CCR-15-2388. Epub 2016 Jun 29.
7
Pediatric high-grade glioma: biologically and clinically in need of new thinking.小儿高级别胶质瘤:在生物学和临床上都需要新思维。
Neuro Oncol. 2017 Feb 1;19(2):153-161. doi: 10.1093/neuonc/now101.
8
Combenefit: an interactive platform for the analysis and visualization of drug combinations.Combenefit:一个用于药物组合分析和可视化的交互式平台。
Bioinformatics. 2016 Sep 15;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. Epub 2016 Apr 25.
9
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.CUDC-907(一种新型口服组蛋白去乙酰化酶(HDAC)和磷脂酰肌醇-3激酶(PI3K)双重抑制剂)在复发或难治性淋巴瘤或多发性骨髓瘤患者中的安全性、耐受性及初步活性:一项开放标签、剂量递增的1期试验。
Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31.
10
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.弥漫性脑桥内生型胶质瘤中驱动基因突变的时空同质性
Nat Commun. 2016 Apr 6;7:11185. doi: 10.1038/ncomms11185.